Study wrapper · #466
Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study.
Editor's note
This single-centre retrospective study in Shanghai looked at whether semaglutide, a GLP-1 receptor agonist widely used for glycaemic control and weight management, is associated with changes in blood eosinophils, a white-cell type relevant to allergic and asthmatic inflammation. Among 371 patients, researchers reported that median eosinophil counts fell from 160 to 110 cells/uL after treatment, with a larger percentage drop in non-obese participants; baseline eosinophil count was the only independent predictor of the reduction. As an uncontrolled before-after chart review, this design cannot separate the drug's effect from weight loss, regression to the mean, or other factors, and there was no placebo group. The eosinophil signal is hypothesis-generating and aligns with growing interest in GLP-1 agonists and inflammation, but it should be read as an association within one clinic, not evidence of a clinical asthma benefit.
Plain-language abstract
Doctors in Shanghai reviewed records of 371 patients newly prescribed semaglutide, a medicine used for blood-sugar and weight management, to see whether it was linked to changes in eosinophils, a type of white blood cell involved in allergies and asthma. After treatment, the middle value for eosinophils dropped from 160 to 110 cells per microlitre, and the share of people with low counts rose. The fall was larger in people who were not obese, and those starting with higher counts saw bigger drops. Because this was a look-back study with no comparison group, it cannot show the drug caused the change; weight loss or other factors may contribute. The authors present it as an early signal worth testing in proper trials.